Evidence map›Paper›PMID 38116572›Full record

ArticleIranian journal of pharmaceutical research : IJPR

Farbod Taghavi Rad, Saied Ghorbian, Bahar Naghavi Gargari, Zeinab Shirvani Farsani, Rasoul Sharifi

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Iranian journal of pharmaceutical research : IJPR. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Farbod Taghavi RadDepartment of Molecular Genetics, Ahar Branch, Islamic Azad University, Ahar, Iran.
Saied GhorbianDepartment of Molecular Genetics, Ahar Branch, Islamic Azad University, Ahar, Iran.ORCID https://orcid.org/0000-0003-0780-3159
Bahar Naghavi GargariDepartment of Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0003-3226-5364
Zeinab Shirvani FarsaniDepartment of Cell and Molecular Biology, Faculty of Life Science and Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Rasoul SharifiDepartment of Biology, Faculty of Basic Sciences, Ahar Branch, Islamic Azad University, Ahar, Iran.
Islamic Azad University of Ahar · IRShahid Beheshti University · IRShahid Beheshti University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Abnormal DNA methylation patterns have been reported in various diseases, including different cancers. CRISPR/Cas9 is a low-cost and highly effective gene editing tool that has lately revolutionized biotechnology. Studies have shown that the CRISPR/Cas9 system can effectively target and correct methylation. Objectives: Telomerase plays a survival role for cancer cells. It is encoded by the Methods: EF1a-hsaCas9-U6-gRNA vector carrying sgRNA and Cas9 hybrids were used to transfect U87 glioma cells. Four and eight μg/mL polybrene concentrations were investigated to improve transfection efficiency. The expression level of Results: The findings demonstrated that gRNA significantly boosted transfection effectiveness. Significant variations were seen in the expression of Conclusions: It appears that the designed CRISPR/Cas9 system can reduce

Indexed as

CRISPR/Cas9GliomahTERT GeneTelomerase

Identifiers

PMID38116572
PMCPMC10728856
OpenAlexW4386097981

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.